Healthcare Organizations Call for FDA Action on Compounding Regulations Amid GLP-1 Shortages
March 23, 2025 - 10:21
Today, the Obesity Action Coalition (OAC) and The Obesity Society (TOS) have taken a significant step by sending a letter to the U.S. Food and Drug Administration (FDA). This letter, supported by over 20 prominent organizations and providers from various sectors of healthcare, emphasizes the urgent need for the FDA to implement and enforce federal regulations concerning compounding practices.
The call to action comes in the wake of recent shortages of GLP-1 medications, which are crucial for the treatment of obesity and related conditions. These shortages have raised serious concerns about patient access to essential therapies. The coalition argues that without stricter oversight and regulation of compounded medications, patients may face continued disruptions in their treatment options.
Healthcare leaders are advocating for a timely response from the FDA to ensure that patients receive the medications they need without interruption, highlighting the importance of regulatory frameworks in safeguarding public health.
MORE NEWS
October 21, 2026 - 20:59
Sea Buckthorn and Respiratory Health: What Pharmacists Need to KnowSea buckthorn is a commonly used herbal for respiratory health, and US pharmacists are knowledgeable in educating patients on herbals, especially during the cold season. Sea buckthorn, known...
October 21, 2026 - 05:08
How You Drink Your Tea May Affect Heart Health, Study FindsThe way you prepare and drink your tea could influence your cardiovascular health, according to a new study. Researchers found that tea itself offers meaningful benefits for the heart, but those...
October 20, 2026 - 23:59
Maryland Expands Reproductive Health Training Program With State FundingThe University of Maryland is broadening a reproductive health initiative with more than $16 million in state grant funds spread across five years. The investment builds on earlier work that has...
October 20, 2026 - 13:46
GLP-1 Drugs Tied to Better Kidney Outcomes in Bipolar Disorder PatientsResearchers have found that GLP-1 receptor agonists, a class of medications commonly prescribed for diabetes and weight management, may offer significant protection for kidney health in adults...